Methods for discontinuing a treatment with a tyrosinekinase inhibitor (tki)

The present invention relates to a method for discontinuing a treatment with a TKI by determining the number and/or frequency of innate CD8(+) T-cells in subject and concluding that the treatment with a TKI should be discontinued when the number and/or frequency of innate CD8 T-cells is higher than the predetermined reference value. Inventors evaluated whether innate CD8(+) T-cells are an early target of CML therapy success. Among peripheral blood effector CD8(+) T-cells, inventors shown that both number and/or frequency and functional signatures of innate CD8(+) T-cells are enhanced as early as 3 months of therapy. Strikingly, they observe that patients with high innate CD8(+) T-cell number and/or frequency at 3 months and/or diagnosis achieve a DMR earlier than patients with low innate CD8(+) T-cell number. Furthermore, a higher number and/or frequency of high innate CD8(+) T-cell patients achieved a stable DMR for over 2 years. Collectively, these findings highlight innate CD8(+) T-cells as a potential marker for both CML therapy success and therapy discontinuation eligibility.

Keywords: BCR-ABL, TKI response prediction
Patent Application number: EP20 305 107.3 on 05/02/2020
PCT/EP2021/052655 on 04/02/2021
Publications:
Sci Rep. 2020 Feb 24 Barbarin et al Innate T-αβ lymphocytes as new immunological components of anti-tumoral off-target effects of the tyrosine kinase inhibitor dasatinib DOI: 10.1038/s41598-020-60195-z

Reference:

BIO19174-D1

Business Developper
contact
Pierre MAZOT
Pierre MAZOT
Business Developer
Patent filling date: 2020-02-05

You might also be interested in